Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy

AIMS: The purpose of this study was to evaluate the effectiveness of a new, fixed, yet individualized dosing regimen of activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for warfarin reversal in the setting of a life-threatening bleeding in a secondary care c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wójcik, Cezary, Schymik, Michelle L., Cure, Eric G.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2009
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840588/
https://www.ncbi.nlm.nih.gov/pubmed/20436891
http://dx.doi.org/10.1007/s12245-009-0125-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840588/
https://www.ncbi.nlm.nih.gov/pubmed/20436891
http://dx.doi.org/10.1007/s12245-009-0125-8

Ejemplares similares